A meta-analysis included 3,612 breast cancer patients encompassing 6 clinical trials, evaluated the efficacy of Atezolizumab (PD-L1 inhibitor) and Pembrolizumab (PD-1 inhibitor) in breast cancer treatment. This evidence concerns the gene CD274 and breast carcinoma.